Results 61 to 70 of about 54,166 (228)

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Binge drinking triggers VGLUT3-mediated glutamate secretion and subsequent hepatic inflammation by activating mGluR5/NOX2 in Kupffer cells

open access: yesNature Communications
Glutamate, a crucial player in hepatic amino acid metabolism, has been relatively unexplored in immune cell activation. We show in a study with male mice that hepatic glutamate accumulates in vesicles of perivenous hepatocytes through vesicular glutamate
Keungmo Yang   +21 more
doaj   +1 more source

Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum

open access: yesFrontiers in Integrative Neuroscience, 2014
Growing awareness of cerebellar involvement in addiction is based on the cerebellum’s intermediary position between motor and reward, potentially acting as an interface between motivational and cognitive functions.
Ana ePalomino   +10 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis

open access: yesNeuropsychiatric Disease and Treatment, 2015
Xiaoqin Yang,1 Guiping Wang,2 Yaodong Wang,3 Xia Yue4 1Department of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, 2Department of Pharmacy, College of Health Sciences, Guangzhou Medical University, 3Department of ...
Yang X, Wang G, Wang Y, Yue X
doaj  

Metabotropic Glutamate2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice

open access: yesFrontiers in Pharmacology, 2018
There is substantial evidence that glutamate can modulate the effects of 5-hydroxytryptamine2A (5-HT2A) receptor activation through stimulation of metabotropic glutamate2/3 (mGlu2/3) receptors in the prefrontal cortex.
Mark J. Benvenga   +7 more
doaj   +1 more source

Astrocyte Regulation of Spinal Circuit Function [PDF]

open access: yesJ Neurochem
Spinal cord astrocytes exist as an additional component of the computational framework that governs both sensory perceptions and motor outputs (left). By integrating local synaptic activity together with signals that reflect whole‐body state (e.g., neuromodulators, immune signals, and vascular signals) into defined input states (Sn), astrocytes adapt ...
Duff M, Li M, Nimmerjahn A.
europepmc   +2 more sources

Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study

open access: yesCerebellum & Ataxias, 2018
Autism is a neurodevelopmental disorder that is first manifested during early childhood. Postmortem experiments have identified significantly elevated expression of metabotropic glutamate receptor 5 (mGluR5) in cerebellar vermis and prefrontal cortex of ...
S. Fatemi   +9 more
semanticscholar   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen   +2 more
wiley   +1 more source

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

open access: yesParkinson's Disease, 2010
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia.
Hugh Chan   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy